Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in …
Benzinga Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with … |
View full post on asthma – Google News